TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tissue Regenix ( (GB:TRX) ) has issued an update.
Tissue Regenix has announced a conditional fundraising of £17.5 million through Secured Convertible Loan Notes to Harwood Private Equity, an existing substantial shareholder. Alongside this, the company plans to cancel its AIM listing due to disproportionate costs and limited benefits, re-register as a private entity, and adopt new articles of association. This strategic move is intended to streamline operations and provide a more cost-effective capital access, impacting its market presence and shareholder engagement.
The most recent analyst rating on (GB:TRX) stock is a Hold with a £8.00 price target. To see the full list of analyst forecasts on Tissue Regenix stock, see the GB:TRX Stock Forecast page.
Spark’s Take on GB:TRX Stock
According to Spark, TipRanks’ AI Analyst, GB:TRX is a Neutral.
The overall stock score is primarily influenced by financial performance, which shows some operational improvements but significant challenges remain. Technical analysis indicates bearish momentum, and valuation metrics reflect ongoing financial struggles. The earnings call provided some positive insights, but these were outweighed by revenue declines and regulatory issues.
To see Spark’s full report on GB:TRX stock, click here.
More about Tissue Regenix
Tissue Regenix is a leading medical device company specializing in regenerative medicine. The company utilizes its patented decellularization technology, dCELL®, to create acellular tissue scaffolds that aid in repairing damaged body structures without rejection. Their products are applied in sports medicine, foot and ankle injuries, and wound care. Tissue Regenix expanded its capabilities by acquiring CellRight Technologies, which focuses on innovative tissue scaffolds for various surgical procedures.
Average Trading Volume: 715,086
Technical Sentiment Signal: Sell
Current Market Cap: £5.16M
For an in-depth examination of TRX stock, go to TipRanks’ Overview page.